Merck & Co., Inc.
For the period ended Feb 3, 2026. Filed Feb 3, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Feb 3, 2026 · Filed Feb 3, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.2 · Table 2b
Table 2b
| GAAP · Acquisition and Divestiture- Related Costs (1) · Restructuring Costs (2) · (Income) Loss from Investments in Equity Securities · Certain Other Items · Adjustment Subtotal · Non-GAAP | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fourth Quarter | |||||||||||
| Cost of sales | $3,828 | 701 | 121 | 822 | $3,006 | ||||||
| Selling, general and administrative | 2,864 | 29 | 16 | 45 | 2,819 | ||||||
| Research and development | 4,585 | 12 | (1) | 11 | 4,574 | ||||||
| Restructuring costs | 51 | 51 | 51 | – | |||||||
| Other (income) expense, net | 126 | (31) | 152 | 121 | 5 | ||||||
| Income Before Taxes | 4,170 | (711) | (187) | (152) | (1,050) | 5,220 | |||||
| Income Tax Provision (Benefit) | 425 | (111 | )(3) | (17 | )(3) | (33 | )(3) | (260 | )(4) | (421) | 846 |
| Net Income | 3,745 | (600) | (170) | (119) | 260 | (629) | 4,374 | ||||
| Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA | 3,743 | (600) | (170) | (119) | 260 | (629) | 4,372 | ||||
| Earnings per Common Share Assuming Dilution | $1.48 | (0.23) | (0.07) | (0.04) | 0.10 | (0.24) | $1.72 | ||||
| Tax Rate | 10.2% | 16.2% | |||||||||
| Full Year | |||||||||||
| Cost of sales | $15,193 | 2,409 | 495 | 2,904 | $12,289 | ||||||
| Selling, general and administrative | 10,816 | 117 | 83 | 200 | 10,616 | ||||||
| Research and development | 17,938 | 72 | 1 | 73 | 17,865 | ||||||
| Restructuring costs | 309 | 309 | 309 | – | |||||||
| Other (income) expense, net | (24) | (79) | 45 | (34) | 10 | ||||||
| Income Before Taxes | 19,936 | (2,519) | (888) | (45) | (3,452) | 23,388 | |||||
| Income Tax Provision (Benefit) | 2,803 | (461 | )(3) | (135 | )(3) | (10 | )(3) | (519 | )(4) | (1,125) | 3,928 |
| Net Income | 17,133 | (2,058) | (753) | (35) | 519 | (2,327) | 19,460 | ||||
| Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA | 17,117 | (2,058) | (753) | (35) | 519 | (2,327) | 19,444 | ||||
| Earnings per Common Share Assuming Dilution | $6.74 | (0.81) | (0.30) | (0.01) | 0.21 | (0.91) | $7.65 | ||||
| Tax Rate | 14.1% | 16.8% | |||||||||
Only the line items that are affected by non-GAAP adjustments are shown.
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1)Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Additionally, research and development expenses for the full year includes Animal Health intangible asset impairment charges. Amounts included in other (income) expense, net, primarily reflect royalty income and a decrease in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture.
(2)Amounts primarily include employee separation costs, accelerated depreciation and asset impairment charges associated with facilities to be closed or divested related to activities under the Company's formal restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
(4) Represents benefits recorded in the fourth quarter and full year due to reductions in reserves for unrecognized income tax benefits resulting from the expiration of the statute of limitations for assessments related to federal income tax return years. The benefit recognized in the fourth quarter relates to the 2020 federal tax return year and the benefit recognized for the full year relates to both the 2020 and 2019 federal tax return years.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.